What to watch with Pharmakogenetik Medicheck and weight loss?

When combining pharmacogenetics (Medicheck) with weight loss, caution is warranted: the provided context lacks specific studies linking genetic variants directly to weight loss drug efficacy. While variants like FTO rs9939609 (GWAS, small BMI effect) or TCF7L2 rs7903146 (moderate diabetes risk) are known, their relevance to pharmacogenetics in weight management is unclear. Medicheck tests often analyze CYP enzymes (e.g., CYP2D6, CYP2C19) that metabolize many drugs – including appetite suppressants or metformin. Without concrete evidence in the given knowledge, the evidence base is mixed. Consumers should not use such test results as sole decision-making tools but seek medical advice. Moreover, many of these tests lack clinical validation (marketing nature). Safety note: self-adjusting medication dosages based on genetic tests can be dangerous.